| Abstract |
[Abstract] Objective: To explore the value of sequential therapy with butylphthalide in the treatment of stable Parkinsons disease patients with mild cognitive impairment. Method: From April 2020 to December 2022, 80 patients diagnosed with stable mild cognitive impairment in Parkinsons disease were selected for this clinical comparative study using an Excel spreadsheet. The patients were randomly divided into groups using a random number table method, with 40 patients receiving donepezil hydrochloride treatment as the control group and 40 patients receiving sequential treatment with ibuprofen in addition to the control group being included in the observation group. Calculate the clinical efficacy and incidence of adverse reactions after treatment, and evaluate the clinical indicators, psychological status, levels of malondialdehyde (MDA) and superoxide dismutase (SOD) before and after treatment. The clinical efficacy of the observation group of 40 patients treated with sequential treatment with butylphthalide was 97.50%, which was higher than that of the control group, P<0.05; the incidence of adverse reactions in the observation group was not statistically significant compared to the control group, P>0.05; the Parkinsons score in the observation group was lower than that of the control group, while the scores of the Simplified Mental State Scale, Montreal Cognitive Assessment Scale, and Quality of Life Scale were higher than those of the control group, P<0.05; the depression self-evaluation scale and anxiety self-evaluation scale were lower than those of the control group, P<0.05; the MDA and SOD scores in the observation group were significantly different from those of the control group, P<0.05. Conclusion: In the treatment of patients with mild cognitive impairment during the stable phase of Parkinsons disease, choosing sequential therapy with butylphthalide can not only improve their physical and mental state, but also alleviate Parkinsons symptoms, promote cognitive function recovery, and enhance the overall quality of life of patients.
|